Algeria vs Lithuania: Cause of death, by non-communicable diseases, female
Algeria
79.9%
in 2021
Lithuania
80.2%
in 2021
Algeria rank
42nd
Lithuania rank
39th
Cause of death, by non-communicable diseases, female over time
- Algeria
- Lithuania
How they compare
Lithuania currently reports 80.2% against 79.9% in Algeria, a difference of 0.3%.
Across all 6 years both countries report, Lithuania has been ahead every year.
Algeria ranks 42nd and Lithuania ranks 39th of 185 countries.
Lithuania has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Algeria | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 72.8% | 92.4% | 19.6% | Lithuania |
| 2010s | 81.4% | 93.9% | 12.5% | Lithuania |
| 2020s | 75.7% | 84.9% | 9.2% | Lithuania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, female, Algeria or Lithuania?
- Lithuania, at 80.2% against 79.9% in Algeria as of 2021.
- What is the difference in cause of death, by non-communicable diseases, female between Algeria and Lithuania?
- 0.3%, with Lithuania ahead.
- How many years of comparable data are there for Algeria and Lithuania?
- 6 years are reported by both, from 2000 to 2021.
- How do Algeria and Lithuania rank globally for cause of death, by non-communicable diseases, female?
- Algeria ranks 42nd and Lithuania ranks 39th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, female (% of total female deaths). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of female deaths due to non-communicable diseases divided by number of all female deaths, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.